biote (BTMD) Scheduled to Post Quarterly Earnings on Tuesday

biote (NASDAQ:BTMD) is set to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect biote to post earnings of $0.05 per share for the quarter. biote has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

biote (NASDAQ:BTMD) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.08 by $0.06. biote had a negative return on equity of 45.10% and a net margin of 1.79%. The firm had revenue of $45.70 million during the quarter, compared to analysts’ expectations of $45.50 million. On average, analysts expect biote to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Stock Performance

Shares of NASDAQ:BTMD traded up $0.08 during trading on Tuesday, hitting $5.56. 8,990 shares of the stock were exchanged, compared to its average volume of 105,445. The company has a market capitalization of $414.39 million, a price-to-earnings ratio of -24.91 and a beta of 0.87. biote has a 1-year low of $3.65 and a 1-year high of $8.22. The company’s fifty day simple moving average is $5.82 and its 200-day simple moving average is $5.17.

Wall Street Analysts Forecast Growth

BTMD has been the topic of several analyst reports. B. Riley started coverage on shares of biote in a report on Tuesday, February 20th. They issued a “buy” rating and a $9.00 price target on the stock. Truist Financial dropped their price objective on biote from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, January 18th. Jefferies Financial Group initiated coverage on shares of biote in a research note on Thursday, February 1st. They issued a “buy” rating and a $6.55 target price on the stock. Finally, Roth Mkm reiterated a “buy” rating and set a $9.00 target price (up previously from $8.00) on shares of biote in a research report on Wednesday, March 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.11.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.